晚期非小细胞肺癌患者免疫检查点抑制剂输注时间与临床结局
该回顾性研究纳入2016至2021年间接受单药抗PD-(L)1治疗的180例晚期非小细胞肺癌患者,分析16:30后输注ICI比例与生存的关系。结果显示,≥20%晚间输注者中位PFS显著更短(4.9 vs 9.4个月,p=0.020),OS数值更短但未达统计学显著(14.0 vs 26.2个月,p=0.090);多因素分析中该比例与PFS的HR为1.44(95%CI 1.01-2.05,p=0.043),但纳入总输注次数后不再显著(HR 1.20,95%CI 0.83-1.75,p=0.329)。
要点
- ≥20%的ICI输注在16:30后(65/180,36%)与更短的中位PFS相关(4.9 vs 9.4个月,log-rank p=0.020)。
- 该输注比例与OS数值上更短相关但未达统计学显著(14.0 vs 26.2个月,log-rank p=0.090)。
- 多因素分析中该比例与PFS的HR为1.44(95%CI 1.01-2.05,p=0.043),但纳入总输注次数后不再显著(HR 1.20,95%CI 0.83-1.75,p=0.329)。
核心结论
- ICI的每日输注时间可能影响晚期NSCLC患者的生存。
- 潜在的预后特征和接受的输注次数可能是混杂因素,与ICI输注时间相关的方差增加有关。
- 作者认为进一步研究可能揭示调节ICI疗效的时间生物学机制。
研究设计与样本
- 回顾性分析2016至2021年间接受任何线数单药抗PD-(L)1治疗的晚期NSCLC患者。
- 共纳入180例患者,77%接受ICI作为二线或更后线治疗,中位输注次数为12次/患者。
- 采用Cox回归模型计算16:30后ICI输注比例与总生存(OS)和无进展生存(PFS)的关联。
主要发现
- 中位年龄65岁(IQR 57-70),112例(62%)为男性,165例(92%)为当前或既往吸烟者,140例(78%)体能状态(PS)为0或1,26例(14%)在ICI开始时接受类固醇治疗。
- 组织学为非鳞癌者139例(77%),转移部位中位数为3个,33%有脑转移。
- ≥20%的ICI输注在16:30后(65/180,36%)的患者中位PFS为4.9个月,<20%晚间输注者为9.4个月(log-rank p=0.020)。
- ≥20%晚间输注者中位OS为14.0个月,<20%者为26.2个月(log-rank p=0.090),数值上更短但未达统计学显著。
- 多因素分析中,≥20%晚间输注未显著增加死亡风险,PS和治疗线数与OS显著相关;该比例与PFS的HR为1.44(95%CI 1.01-2.05,p=0.043),但纳入总输注次数后不再显著(HR 1.20,95%CI 0.83-1.75,p=0.329)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 潜在的预后特征和接受的输注次数可能是混杂因素,与ICI输注时间相关的方差增加有关。
- 作者认为进一步研究可能揭示调节ICI疗效的时间生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine whether immune checkpoint inhibitors (ICI) time-of-day infusion might influence the survival of patients with advanced non-small cell lung cancer (NSCLC). METHODS: We retrospectively analysed patients who received single-agent anti-PD-(L)1 therapy in any line between 2016 and 2021. We calculated by Cox regression models the association between the proportion of ICI infusions received after 16:30h and overall survival (OS) and progression-free survival (PFS). RESULTS: 180 patients were included, 77% received ICI as second- or further-line (median of 12 infusions/patient). The median age was 65 years (IQR 57-70), 112 patients (62%) were male, 165 (92%) were current or former tobacco smokers, 140 (78%) had performance status (PS) 0 or 1, 26 (14%) were on steroid therapy at ICI initiation. Histology was non-squamous for 139 (77%), the median number of metastatic sites was 3, and 33% had brain metastases. Patients who received at least 20% of ICI infusions after 16:30h (65 out of 180, 36%) had a statistically significant shorter median PFS as compared with patients receiving less than 20% of infusions in the evening (4.9 vs 9.4 months, log-rank p = 0.020), while numerical but not statistical shorter OS was observed (14.0 vs 26.2 months, log-rank p = 0.090). In the multivariate analysis, receiving at least 20% of evening infusions did not significantly increase the risk of death, while PS and line of treatment were significantly correlated with the OS. On the contrary, a proportion of ICI administration after 16:30h ≥20% conferred an HR for the PFS of 1.44 (95% CI: 1.01-2.05, p = 0.043), but this prognostic effect was not found when including in the model the total number of ICI infusions received (HR 1.20, 95% CI: 0.83-1.75, p = 0.329). CONCLUSION: Time-of-day infusion of ICI may impact the survival of patients with advanced NSCLC. Underlying prognostic characteristics and the number of infusions received could represent conceivable confounding factors, linked to increased variance related to ICI infusion timing. Nonetheless, further studies may unravel chronobiological mechanisms modulating ICI efficacy.
引用
- Rousseau A, Tagliamento M, Auclin E, et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023. PMID: 36758475. doi:10.1016/j.ejca.2023.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。